A PD-L1 latecomer hoping to break into the market
https://scrip.pharmaintelligence.informa.com/SC099801/ImmuneOncia-A-PDL1-Latecomer-Hoping-To-Break-Into-The-Market
ImmuneOncia “First anti-PD-L1 immunotherapy drug in Korea, clinical phase next year”
ImmuneOncia “First anti-PD-L1 immunotherapy drug in Korea, clinical phase next year” Yuhan-Sorrento joint venture company, fastest development in Korea.. “Later to expedite the development of ‘macrophage-activating anti-CD47 antibody’” “We plan to apply anti-PD-L1 ‘IMC-001’ antibody [...]
Yuhan Corporation And Sorrento Therapeutics Form Joint Venture Company – ImmuneOncia
https://www.fiercebiotech.com/biotech/yuhan-corporation-and-sorrento-therapeutics-form-joint-venture-company-immuneoncia